FDA panel favors easing safety limits on Avandia

FDA panel favors easing safety limits on Avandia

The vote is a recommendation to the FDA and is not binding. The panel ruling is a small victory for British drugmaker Glaxo after more than a half-decade defending the safety of Avandia, which was once the best-selling diabetes drug in the world.

5
Like
Save

Comments

Write a comment

*